Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Temmune Therapeutics N V has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, so the profile presents a single examination track without distribution across multiple assignments.
DAHLIN, HEATHER RAQUEL is the busiest examiner, with 1 pending matter. The matching examiner and art-unit counts make this a focused prosecution matter. Practitioners can direct docket review, claim strategy, and response preparation to the single listed examination record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 1 | 41.9% | +46.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18891367 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891367 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | DAHLIN, HEATHER RAQUEL | 1629 | §112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTemmune Therapeutics N V has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Heather Raquel Dahlin has the most, with 1 of Temmune Therapeutics N V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.